Ligand Pharma (LGND) Tops Q1 EPS by 29c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $315.51 +0.63%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.41, $0.29 better than the analyst estimate of $1.12. Revenue for the quarter came in at $55.2 million versus the consensus estimate of $62.85 million.
GUIDANCE:
Ligand Pharma sees 2021 EPS of $6.15, versus the consensus of $6.17. Ligand Pharma sees 2021 revenue of $291 million, versus the consensus of $292 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
- SharkNinja (SN) Tops Q3 EPS by 74c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
